Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
AXON vs PDSB: Contrasting a Scaled Public-Safety Leader with a High-Volatility Biotech

AXON vs PDSB: Contrasting a Scaled Public-Safety Leader with a High-Volatility Biotech

Key Takeaways

  • AXON is a large, profitable public-safety technology leader with roughly $3.2 billion in trailing revenue, while PDSB is a clinical-stage biotech with no product revenue yet.
  • Recent momentum diverges sharply: PDSB has delivered a triple-digit percentage surge over recent months on financing and clinical news, whereas AXON is rebounding after a prolonged drawdown despite strong underlying revenue growth.
  • AXON derives value from recurring software and hardware contracts and government budgets, while PDSB is driven almost entirely by binary clinical-trial and funding catalysts.
  • Risk profiles are fundamentally different: AXON carries valuation and margin risks, while PDSB faces liquidity, dilution, and regulatory risk.
  • Wall Street currently assigns a "Buy" consensus to AXON with a far larger analyst base than PDSB, which is thinly covered but carries high percentage-based upside targets.
  • For more detail, explore AXON Major News and AXON Today's Price Move, as well as PDSB Major News and PDSB Today's Price Move.
  • To see how automated strategies are positioning across the market, explore the curated Trending AI Robots page.

Setting the Stage: Two Distinct Equity Profiles

Placing AXON and PDSB side by side highlights two very different equity profiles: a scaled, profitable public-safety technology franchise versus a small, pre-revenue oncology developer. They do not compete in the same industry, yet both have drawn intense investor attention for opposite reasons. This comparison is most relevant for traders weighing a high-quality growth name trading below its recent highs against a high-volatility biotech responding to financing and pipeline news. Readers interested in relative performance, market positioning, and how AI-driven signals read each setup may find the contrast instructive. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in their respective industries.

AXON: Operational Strength Amid Valuation Reset

Axon Enterprise, Inc. designs and sells public-safety technology, including TASER energy devices, body-worn and in-car cameras, drones and robotics, digital-evidence software, and AI-driven productivity tools. Its growth engine centers on converting hardware customers into recurring software and services contracts. Trailing twelve-month revenue of roughly $3.2 billion grew more than 30% year over year, with annual recurring revenue reaching approximately $1.6 billion and net revenue retention near 126%. From what I see, that operational strength stands out even as the stock has lagged.

Despite that foundation, AXON has lagged broader indexes for much of the year, falling more than 20% year to date and about 40% over the trailing twelve months as investors reassessed its premium valuation and thinner near-term margins. Recent weeks have shown a rebound, aided by the launch of the Axon Body 5 camera, which the company says offers substantially greater on-device AI processing power. Analysts broadly maintain a "Buy" consensus, though several firms have trimmed price targets as the stock reset.

PDSB: Catalyst-Driven Volatility in Biotech

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies. Its lead programs include PDS0101, an HPV16-targeted therapy, and PDS0301, an immunotherapy being advanced toward a Phase 3 trial in metastatic colorectal cancer. The company generates no product revenue and reported a net loss in recent periods, with a market capitalization in the low hundreds of millions of dollars.

Recent market activity has been exceptionally volatile. PDSB surged by triple digits over a matter of weeks after a Nant Capital-led financing and renewed focus on PDS0301, lifting the shares from well below one dollar. The company also streamlined operations, reducing its workforce significantly to preserve capital. Analysts who cover the name maintain Buy ratings with price targets well above the current price, but funding, dilution, and execution risks remain central to the story. I’m watching this closely because the binary nature of the catalysts makes timing especially important.

Exploring Automated Strategies

Tickeron's Trending AI Robots page highlights a curated selection of AI trading bots drawn from a much larger universe of automated strategies. Tickeron offers hundreds of AI trading bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this featured section. Each bot operates with its own trading style, strategy, timeframe, performance history, and set of tickers, allowing users to compare statistics such as trade frequency, win rates, and drawdown profiles. Browsing this section can help traders identify systematic approaches aligned with the current environment.

Key Differences in Business Models and Risks

The core contrast is one of maturity versus optionality. AXON is an established business with growing revenue, a large contracted backlog, and recurring software economics, but it trades at a premium price-to-earnings (P/E) ratio that demands consistent execution. PDSB offers no earnings base, so its value rests on clinical data readouts, regulatory milestones, and continued access to capital.

Growth drivers also differ. AXON is propelled by AI adoption, premium software bundles, and counter-drone programs tied to public-sector budgets. PDSB depends on advancing its oncology pipeline and converting early data into a registrational path. Momentum has favored PDSB in percentage terms recently, while AXON has begun stabilizing after a prolonged slide. Risk profiles, sector exposure, and liquidity differ so substantially that the two are best understood as serving different investor objectives rather than as direct substitutes.

AI-Driven Insights on the Pair

Based on observable trend consistency, stability, and catalyst structure, Tickeron's AI would likely favor AXON for its more durable, established business model and recurring revenue base, while treating PDSB as a higher-volatility, event-driven opportunity. The probabilistic read suggests AXON offers relatively steadier positioning despite valuation concerns, whereas PDSB carries greater upside potential tied to binary clinical and funding outcomes. Neither is without risk, and the appropriate choice depends on an investor's tolerance for volatility and time horizon.

My Experience with Tickeron’s Trending AI Robots

I have found Tickeron’s Trending AI Robots page particularly useful when comparing setups like these. It surfaces a focused list of automated strategies that are performing well in the current environment, complete with performance metrics and ticker coverage. This helps me quickly assess how systematic approaches are positioning across both stable growth names and higher-volatility opportunities without having to review every bot individually.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AXON, PDSB

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


AXON's RSI Indicator descends into oversold zone

The RSI Indicator for AXON moved into overbought territory on November 20, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 270 of 367 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 52 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 36.83B. The market cap for tickers in the group ranges from 4.49 to 1.77T. SPCX holds the highest valuation in this group at 1.77T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -16%. For the same Industry, the average monthly price growth was -17%, and the average quarterly price growth was -35%. POWW experienced the highest price growth at 13%, while VWAV experienced the biggest fall at -55%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 41%. For the same stocks of the Industry, the average monthly volume growth was 16% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 53
Price Growth Rating: 65
SMR Rating: 78
Profit Risk Rating: 79
Seasonality Score: -14 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company

Industry AerospaceDefense

Industry
Biotechnology
Address
17800 North 85th Street
Phone
+1 480 991-0797
Employees
6300
Web
https://www.axon.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.